Harnessing Multi-Omics In AI-Immunology™ For Developing Shared Cancer Vaccines Targeting Endogenous Retroviruses

• Endogenous retroviruses – a novel antigen source which is promising for cancer vaccines
• The development of an ERV targeting cancer vaccine using Evaxion’s AI-Immunology™ platform
• Preclinical validation of an ERV hotspot vaccine which leads to tumor control and T-cell responses​

Speakers:

Nikolas Thuesen

Bioinformatician

Evaxion Biotech